Suman Pasupuleti, MD
Clinical Cardiac Electrophysiology · Inverness, FLNPI 1851503809
Payments from drug & device makers
Across 344 payments — averaging $522.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$99K
- Novartis$28K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$22K
- Abbott$14K
- Johnson & Johnson$11K
- Medtronic$2K
- plus $3K from 31 others
What the payments were for
- Consulting fees$2,8085%
- Speaking & faculty fees$40,65071%
- Travel & lodging$4,9159%
- Food & beverage$8,87815%
- Education$2230%
- Other$380%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 27 | $99,276 |
| Novartis | 12 | $28,319 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 39 | $22,228 |
| Abbott | 76 | $14,138 |
| Johnson & Johnson | 22 | $11,154 |
| Medtronic(2 entities) | 57 | $1,768 |
| Impulse Dynamics (USA) Inc. | 6 | $390 |
| Biosense Webster, Inc. | 4 | $240 |
| Pfizer | 13 | $223 |
| Amgen | 13 | $222 |
| Alnylam Pharmaceuticals Inc. | 6 | $202 |
| E.r. Squibb & Sons, L.L.C. | 11 | $191 |
| Boston Scientific | 7 | $142 |
| Edwards Lifesciences | 1 | $136 |
| Nuwellis, Inc. | 3 | $130 |
| Esperion Therapeutics, Inc. | 8 | $128 |
| Tesaro, Inc. | 1 | $125 |
| Merck | 5 | $118 |
| Amarin Pharma, Inc. | 4 | $84 |
| Kestra Medical Technology Services, Inc. | 3 | $83 |
| Boehringer Ingelheim | 1 | $82 |
| Novo Nordisk | 4 | $78 |
| ZOLL Circulation Inc | 2 | $52 |
| Bardy Diagnostics, Inc. | 3 | $41 |
| Lexicon Pharmaceuticals, Inc. | 2 | $38 |
| Welch Allyn | 1 | $38 |
| Sanofi-aventis U.S. LLC | 2 | $35 |
| Inari Medical, Inc. | 1 | $29 |
| Teleflex LLC | 2 | $29 |
| Biotronik Inc. | 1 | $28 |
| Sanofi | 1 | $21 |
| Bayer | 1 | $19 |
| Innovation Technologies Inc | 1 | $17 |
| Astellas Pharma US Inc | 1 | $16 |
| Cardiva Medical, Inc. | 1 | $16 |
| Atricure, Inc. | 1 | $15 |
| Cvrx, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LifeVest$21,481
- XARELTO$10,851
- FARXIGA$9,291
- Ensite Cardiac Mapping System$3,628
- CardioMEMS HF System$2,808
- Cardiovascular- Research only$996
- OPTIMIZER$353
- Micra$204
- HeartMate 3 Left Ventricular Dev$192
- LINQ II$171
- COBALT DR MRI SURESCAN$131
- ZEJULA$125
- Carto 3 System$121
- Aquadex$102
How this compares
$179,860 in reported general payments places this provider in the 80th percentile of 249 clinical cardiac electrophysiology providers in Florida.
See all clinical cardiac electrophysiology providers in Florida →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 305 | $395,049 |
| XareltoRivaroxaban | 330 | $364,406 |
| FarxigaDapagliflozin Propanediol | 242 | $284,241 |
| EntrestoSacubitril/Valsartan | 152 | $188,308 |
| Repatha SureclickEvolocumab | 39 | $53,256 |
| JardianceEmpagliflozin | 27 | $44,845 |
| Praluent PenAlirocumab | 25 | $19,765 |
| NexlizetBempedoic Acid/Ezetimibe | 22 | $12,643 |
| Metoprolol Succinate | 765 | $12,384 |
| BrilintaTicagrelor | 12 | $11,219 |
| Ranolazine ErRanolazine | 61 | $9,586 |
| Atorvastatin Calcium | 623 | $8,611 |
| Flecainide Acetate | 110 | $7,817 |
| CorlanorIvabradine Hcl | 13 | $7,423 |
| VascepaIcosapent Ethyl | 11 | $7,397 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $223 | $395,049305 claims |
| Johnson & JohnsonXarelto | $11,154 | $364,406330 claims |
| AstraZenecaFarxiga, Brilinta | $99,276 | $295,460254 claims |
| NovartisEntresto | $28,319 | $188,308152 claims |
| Boehringer IngelheimJardiance | $82 | $44,84527 claims |
| Esperion Therapeutics, Inc.Nexlizet | $128 | $12,64322 claims |
| AmgenCorlanor | $222 | $7,42313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 249 clinical cardiac electrophysiology providers in Florida.
Other clinical cardiac electrophysiology in Inverness
- Jose Osorio FilhoMiami$16.4M
- Saumil OzaJacksonville$4.1M
- Usman SiddiquiWinter Park$3.6M
- David KenigsbergFort Lauderdale$1.3M
- Venkata SagiJacksonville$1.2M
- Raul WeissMiami Beach$1.1M
- Robert FishelAtlantis$1.1M
- Naushad ShaikKissimmee$1.1M
- Neal KaveshLakeland$967K
- Antonio MorettaSarasota$891K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.